Biomind Labs Inc. BMNDF
Set alert
At close · Oct 30
- YTD
- +119.47%
- 1 year
- +1,483.54%
- Open
- 0.2502
- Prev close
- 0.2502
- Mkt cap
- 19.41M
- Vol
- 1.00K
- Avg vol
- 1.05K
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.2502
- High
- 0.2502
News
2 months ago accessnewswire.com
Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND) (OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming…
6 months ago accessnewswire.com
Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States
A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20,…
9 months ago accessnewswire.com
Biomind Labs Announces CAD $2.52 Million Private Placement Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC…
11 months ago accessnewswire.com
Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood
BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company")…
11 months ago accessnewswire.com
Biomind Labs Announces Revocation of Cease Trade Order
TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has…
11 months ago accessnewswire.com
Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board
TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents…
1 year ago accesswire.com
Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
TORONTO, ON / ACCESSWIRE / November 20, 2024 / Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI) , a leading biotech company at the forefront of…
2 years ago accesswire.com
Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways
TORONTO, ON / ACCESSWIRE / July 18, 2024 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a leading biotech company dedicated to developing the next-generation…
2 years ago businesswire.com
Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer's Disease
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to…
3 years ago businesswire.com
Biomind Labs Provides Corporate Update
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of…
3 years ago businesswire.com
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of…
3 years ago benzinga.com
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ: GHRS) shares closed up 6.63% at $11.74